- Home
- RCEL vs SRZN Comparison
RCEL vs SRZN Comparison
Compare RCEL & SRZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCEL
- SRZN
- Stock Information
- Founded
- RCEL N/A
- SRZN 2015
- Country
- RCEL United States
- SRZN United States
- Employees
- RCEL N/A
- SRZN N/A
- Industry
- RCEL Medical/Dental Instruments
- SRZN Medicinal Chemicals and Botanical Products
- Sector
- RCEL Health Care
- SRZN Health Care
- Exchange
- RCEL Nasdaq
- SRZN Nasdaq
- Market Cap
- RCEL 107.8M
- SRZN 120.0M
- IPO Year
- RCEL N/A
- SRZN N/A
- Fundamental
- Price
- RCEL $3.42
- SRZN $12.50
- Analyst Decision
- RCEL Buy
- SRZN Strong Buy
- Analyst Count
- RCEL 5
- SRZN 2
- Target Price
- RCEL $11.80
- SRZN $38.50
- AVG Volume (30 Days)
- RCEL 260.2K
- SRZN 38.5K
- Earning Date
- RCEL 11-06-2025
- SRZN 11-07-2025
- Dividend Yield
- RCEL N/A
- SRZN N/A
- EPS Growth
- RCEL N/A
- SRZN N/A
- EPS
- RCEL N/A
- SRZN N/A
- Revenue
- RCEL $74,884,000.00
- SRZN $12,621,000.00
- Revenue This Year
- RCEL $20.40
- SRZN N/A
- Revenue Next Year
- RCEL $32.94
- SRZN N/A
- P/E Ratio
- RCEL N/A
- SRZN N/A
- Revenue Growth
- RCEL 38.32
- SRZN N/A
- 52 Week Low
- RCEL $3.37
- SRZN $5.90
- 52 Week High
- RCEL $14.16
- SRZN $18.17
- Technical
- Relative Strength Index (RSI)
- RCEL 28.06
- SRZN 39.47
- Support Level
- RCEL $3.88
- SRZN $11.39
- Resistance Level
- RCEL $3.91
- SRZN $14.38
- Average True Range (ATR)
- RCEL 0.23
- SRZN 0.56
- MACD
- RCEL -0.05
- SRZN -0.23
- Stochastic Oscillator
- RCEL 0.00
- SRZN 36.87
About RCEL Avita Medical Inc.
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently in rollout across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.
About SRZN Surrozen Inc.
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS).